These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
377 related articles for article (PubMed ID: 33041226)
1. Association of Consensus Molecular Subtypes and Molecular Markers With Clinical Outcomes in Patients With Metastatic Colorectal Cancer: Biomarker Analyses From LUME-Colon 1. Lenz HJ; Argiles G; Yoshino T; Tejpar S; Ciardiello F; Braunger J; Salnikov AV; Gabrielyan O; Schmid R; Höfler J; Kitzing T; Van Cutsem E Clin Colorectal Cancer; 2021 Mar; 20(1):84-95.e8. PubMed ID: 33041226 [TBL] [Abstract][Full Text] [Related]
2. Consensus molecular subgroups (CMS) of colorectal cancer (CRC) and first-line efficacy of FOLFIRI plus cetuximab or bevacizumab in the FIRE3 (AIO KRK-0306) trial. Stintzing S; Wirapati P; Lenz HJ; Neureiter D; Fischer von Weikersthal L; Decker T; Kiani A; Kaiser F; Al-Batran S; Heintges T; Lerchenmüller C; Kahl C; Seipelt G; Kullmann F; Moehler M; Scheithauer W; Held S; Modest DP; Jung A; Kirchner T; Aderka D; Tejpar S; Heinemann V Ann Oncol; 2019 Nov; 30(11):1796-1803. PubMed ID: 31868905 [TBL] [Abstract][Full Text] [Related]
3. CMS-dependent prognostic impact of KRAS and BRAFV600E mutations in primary colorectal cancer. Smeby J; Sveen A; Merok MA; Danielsen SA; Eilertsen IA; Guren MG; Dienstmann R; Nesbakken A; Lothe RA Ann Oncol; 2018 May; 29(5):1227-1234. PubMed ID: 29518181 [TBL] [Abstract][Full Text] [Related]
4. Analysis of circulating DNA and protein biomarkers to predict the clinical activity of regorafenib and assess prognosis in patients with metastatic colorectal cancer: a retrospective, exploratory analysis of the CORRECT trial. Tabernero J; Lenz HJ; Siena S; Sobrero A; Falcone A; Ychou M; Humblet Y; Bouché O; Mineur L; Barone C; Adenis A; Yoshino T; Goldberg RM; Sargent DJ; Wagner A; Laurent D; Teufel M; Jeffers M; Grothey A; Van Cutsem E Lancet Oncol; 2015 Aug; 16(8):937-48. PubMed ID: 26184520 [TBL] [Abstract][Full Text] [Related]
5. The prognostic impact of consensus molecular subtypes (CMS) and its predictive effects for bevacizumab benefit in metastatic colorectal cancer: molecular analysis of the AGITG MAX clinical trial. Mooi JK; Wirapati P; Asher R; Lee CK; Savas P; Price TJ; Townsend A; Hardingham J; Buchanan D; Williams D; Tejpar S; Mariadason JM; Tebbutt NC Ann Oncol; 2018 Nov; 29(11):2240-2246. PubMed ID: 30247524 [TBL] [Abstract][Full Text] [Related]
6. Relative contribution of clinicopathological variables, genomic markers, transcriptomic subtyping and microenvironment features for outcome prediction in stage II/III colorectal cancer. Dienstmann R; Villacampa G; Sveen A; Mason MJ; Niedzwiecki D; Nesbakken A; Moreno V; Warren RS; Lothe RA; Guinney J Ann Oncol; 2019 Oct; 30(10):1622-1629. PubMed ID: 31504112 [TBL] [Abstract][Full Text] [Related]
7. The Evolving Role of Consensus Molecular Subtypes: a Step Beyond Inpatient Selection for Treatment of Colorectal Cancer. Ros J; Baraibar I; Martini G; Salvà F; Saoudi N; Cuadra-Urteaga JL; Dienstmann R; Tabernero J; Élez E Curr Treat Options Oncol; 2021 Nov; 22(12):113. PubMed ID: 34741675 [TBL] [Abstract][Full Text] [Related]
8. Nintedanib for the treatment of patients with refractory metastatic colorectal cancer (LUME-Colon 1): a phase III, international, randomized, placebo-controlled study. Van Cutsem E; Yoshino T; Lenz HJ; Lonardi S; Falcone A; Limón ML; Saunders M; Sobrero A; Park YS; Ferreiro R; Hong YS; Tomasek J; Taniguchi H; Ciardiello F; Stoehr J; Oum'Hamed Z; Vlassak S; Studeny M; Argiles G Ann Oncol; 2018 Sep; 29(9):1955-1963. PubMed ID: 30010751 [TBL] [Abstract][Full Text] [Related]
9. [Characterization of patients with sporadic colorectal cancer following the new Consensus Molecular Subtypes (CMS)]. Wielandt AM; Villarroel C; Hurtado C; Simian D; Zamorano D; Martínez M; Castro M; Vial MT; Kronberg U; López-Kostner F Rev Med Chil; 2017 Apr; 145(4):419-430. PubMed ID: 28748988 [TBL] [Abstract][Full Text] [Related]
10. TP53 mutation status and consensus molecular subtypes of colorectal cancer in patients from Rwanda. Nzitakera A; Uwamariya D; Kato H; Surwumwe JB; Mbonigaba A; Ndoricyimpaye EL; Uwamungu S; Manirakiza F; Ndayisaba MC; Ntakirutimana G; Seminega B; Dusabejambo V; Rutaganda E; Kamali P; Ngabonziza F; Ishikawa R; Watanabe H; Rugwizangoga B; Baba S; Yamada H; Yoshimura K; Sakai Y; Sugimura H; Shinmura K BMC Cancer; 2024 Oct; 24(1):1266. PubMed ID: 39394554 [TBL] [Abstract][Full Text] [Related]
12. Clinical Value of Consensus Molecular Subtypes in Colorectal Cancer: A Systematic Review and Meta-Analysis. Ten Hoorn S; de Back TR; Sommeijer DW; Vermeulen L J Natl Cancer Inst; 2022 Apr; 114(4):503-516. PubMed ID: 34077519 [TBL] [Abstract][Full Text] [Related]
15. Prognostic Implications of Mucinous Differentiation in Metastatic Colorectal Carcinoma Can Be Explained by Distinct Molecular and Clinicopathologic Characteristics. Khan M; Loree JM; Advani SM; Ning J; Li W; Pereira AAL; Lam M; Raghav K; Morris VK; Broaddus R; Maru D; Overman MJ; Kopetz S Clin Colorectal Cancer; 2018 Dec; 17(4):e699-e709. PubMed ID: 30205948 [TBL] [Abstract][Full Text] [Related]
16. Role of circulating free DNA in evaluating clinical tumor burden and predicting survival in Chinese metastatic colorectal cancer patients. Xu X; Yu Y; Shen M; Liu M; Wu S; Liang L; Huang F; Zhang C; Guo W; Liu T BMC Cancer; 2020 Oct; 20(1):1006. PubMed ID: 33066758 [TBL] [Abstract][Full Text] [Related]
17. Association Between Baseline Circulating Tumor Cells, Molecular Tumor Profiling, and Clinical Characteristics in a Large Cohort of Chemo-naïve Metastatic Colorectal Cancer Patients Prospectively Collected. Sastre J; Orden V; Martínez A; Bando I; Balbín M; Bellosillo B; Palanca S; Peligros Gomez MI; Mediero B; Llovet P; Moral VM; Viéitez JM; García-Alfonso P; Calle SG; Ortiz-Morales MJ; Salud A; Quintero G; Lopez C; Díaz-Rubio E; Aranda E; Clin Colorectal Cancer; 2020 Sep; 19(3):e110-e116. PubMed ID: 32278676 [TBL] [Abstract][Full Text] [Related]
18. Immunohistochemistry-Based Consensus Molecular Subtypes as a Prognostic and Predictive Biomarker for Adjuvant Chemotherapy in Patients with Stage II Colorectal Cancer. Li Y; Yao Q; Zhang L; Mo S; Cai S; Huang D; Peng J Oncologist; 2020 Dec; 25(12):e1968-e1979. PubMed ID: 32926498 [TBL] [Abstract][Full Text] [Related]